Fig 1: Editing of PDZD7 reduces its oncogenic ability.(A) WB analysis of ADAR2, DAP3, and actin expression in the indicated EC109 cells. (B and C) Quantification of foci formation (B) or soft agar colony formation (C) induced in the indicated cells. (D) Diagram of PDZD7 gene locus indicates an A-to-I RNA editing at Chr10:102777342 leads to a stop codon to tryptophan substitution, generating an 18–amino acid extension at its C terminus. (E) Dot plots showing editing level changes of PDZD7 transcripts between tumors (T) and their corresponding nontumor (NT) samples (n = 46). Red dot: ≥5%; blue dot: ≤−5%; gray dot: between −5 and 5%. (F) Sequence chromatograms show the editing of PDZD7 in three representative pairs of ESCC tumors and NT samples. (G) Sequence chromatograms illustrate the editing of PDZD7 in the indicated cells. (H to J) PDZD7 RNA expression, protein expression, and editing level are analyzed by quantitative reverse transcription PCR (H), WB (I), and Sanger sequencing (J) respectively, in EC109 cells stably expressing PDZD7WT and PDZD7Stop518W or coexpressing PDZD7WT and PDZD7Stop518W. (K and L) Quantification of foci formation (K) or soft agar colony formation (L) induced in the indicated stable cells. (B, C, K, and L) Data are presented as the mean ± SD of triplicate wells from a representative experiment. Statistical significance is determined by unpaired, two-tailed Student’s t test (*P < 0.05; **P < 0.01).